tiprankstipranks
Trending News
More News >
Cyclopharm Limited (AU:CYC)
ASX:CYC
Australian Market
Advertisement

Cyclopharm Limited (CYC) AI Stock Analysis

Compare
15 Followers

Top Page

AU:CYC

Cyclopharm Limited

(Sydney:CYC)

Rating:45Neutral
Price Target:
AU$1.00
▼(-7.41%Downside)
The overall stock score reflects significant financial challenges with consistent losses and negative cash flows, despite some revenue growth. Technical analysis indicates some short-term positive trends, but these are overshadowed by poor valuation metrics, including a negative P/E ratio and no dividend yield, suggesting substantial risks.

Cyclopharm Limited (CYC) vs. iShares MSCI Australia ETF (EWA)

Cyclopharm Limited Business Overview & Revenue Model

Company DescriptionCyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, and internationally. It operates through Technegas and Molecular Imaging segments. The Technegas segment offers diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism. This segment also distributes third party products to the diagnostic imaging sector. The Molecular Imaging segment provides radiopharmaceuticals that are used by physicians in the detection of cancer, neurological disorders, and cardiac diseases. The company serves nuclear medicine departments. Cyclopharm Limited was founded in 1986 and is headquartered in Kingsgrove, Australia.
How the Company Makes MoneyCyclopharm Limited generates revenue through the manufacture and sale of its proprietary product, Technegas, which is widely used in nuclear medicine for diagnostic imaging of respiratory conditions. Revenue is primarily derived from the sale of Technegas generators and the associated consumables needed for its operation. The company also benefits from service and maintenance agreements related to the equipment. Cyclopharm's earnings are bolstered by its global distribution network, expanding its market reach beyond Australia to Europe, Asia, and North America. Strategic partnerships and collaborations with healthcare providers and research institutions also play a significant role in driving sales and expanding their technological offerings, further contributing to the company's revenue streams.

Cyclopharm Limited Financial Statement Overview

Summary
Cyclopharm Limited is facing significant financial challenges with consistent losses and negative cash flows, despite some revenue growth. The company's strong equity position provides some financial stability, but the lack of profitability and cash flow generation poses substantial risks to its financial health.
Income Statement
35
Negative
Cyclopharm Limited has shown consistent growth in revenue over the years, with a revenue growth rate of 1.6% from 2023 to 2024. However, the company is struggling with profitability, evidenced by persistent negative EBIT and net income, resulting in negative profit margins. Despite some growth in gross profit, the absence of positive net income and EBIT indicates significant challenges in operational efficiency and profitability.
Balance Sheet
45
Neutral
The balance sheet shows a relatively strong equity position with a Debt-to-Equity ratio of 0.19, indicating low leverage. The equity ratio stands at 68.8%, reflecting financial stability and a cushion against liabilities. However, the company has been consistently reporting net losses, impacting the return on equity negatively.
Cash Flow
30
Negative
Cyclopharm Limited's cash flow statement reveals ongoing challenges in generating positive cash flow, with a negative operating cash flow and free cash flow in 2024. The free cash flow growth rate and operating cash flow to net income ratio are concerning, indicating difficulties in sustaining operations through internal cash generation.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue27.57M27.14M23.22M17.70M14.68M
Gross Profit17.93M4.50M5.94M3.20M2.08M
EBITDA-13.69M-3.03M-5.36M-4.19M-4.86M
Net Income-13.20M-4.70M-6.61M-5.04M-6.04M
Balance Sheet
Total Assets62.13M45.91M49.54M55.74M28.28M
Cash, Cash Equivalents and Short-Term Investments20.57M11.73M20.30M29.25M1.87M
Total Debt8.29M4.23M4.33M4.51M4.71M
Total Liabilities19.40M13.65M13.01M12.67M11.16M
Stockholders Equity42.73M32.26M36.54M43.07M17.12M
Cash Flow
Free Cash Flow-13.55M-7.74M-8.21M-2.79M-9.47M
Operating Cash Flow-12.57M-7.20M-6.66M-1.63M-8.93M
Investing Cash Flow-971.86K-508.47K-1.55M-1.16M-874.19K
Financing Cash Flow22.22M-1.02M-725.64K30.17M-985.96K

Cyclopharm Limited Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price1.08
Price Trends
50DMA
1.06
Negative
100DMA
1.16
Negative
200DMA
1.44
Negative
Market Momentum
MACD
<0.01
Negative
RSI
52.80
Neutral
STOCH
74.56
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:CYC, the sentiment is Neutral. The current price of 1.08 is above the 20-day moving average (MA) of 1.01, above the 50-day MA of 1.06, and below the 200-day MA of 1.44, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 52.80 is Neutral, neither overbought nor oversold. The STOCH value of 74.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:CYC.

Cyclopharm Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (46)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
61
Neutral
AU$203.57M-4.06%20.36%64.81%
60
Neutral
AU$56.70M-8.08%-5.62%-225.71%
49
Neutral
AU$148.37M-58.61%-74.88%
46
Neutral
C$201.68M-3.28-23.14%1.87%20.75%-0.36%
45
Neutral
AU$120.03M-35.20%4.68%-155.42%
$70.78M-51.08%
41
Neutral
AU$121.04M-52.37%471.29%-4.58%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:CYC
Cyclopharm Limited
1.08
-0.52
-32.50%
AU:CMP
Compumedics Limited
0.30
0.00
0.00%
IPDQF
Impedimed Limited
0.05
0.00
0.00%
AU:ARX
Aroa Biosurgery Ltd
0.59
-0.04
-6.35%
AU:EMV
EMvision Medical Devices Ltd.
1.73
-0.26
-13.07%
AU:4DX
4DMedical Ltd
0.26
-0.26
-50.00%

Cyclopharm Limited Corporate Events

Cyclopharm Strengthens U.S. Sales Strategy with Key Appointment
Jul 15, 2025

Cyclopharm Limited has appointed Thomas Lukas as Vice President of Sales in the United States to lead a new Business Development Team, aiming to accelerate sales of Technegas in the U.S. market. This strategic hire is part of Cyclopharm’s multi-stage U.S. sales strategy, which includes expanding their sales operations and increasing the adoption of Technegas across U.S. hospital systems. The company is capitalizing on the growing awareness of Technegas’ clinical value, supported by established reimbursement and federal engagements, as well as strong clinical advocacy.

The most recent analyst rating on (AU:CYC) stock is a Buy with a A$2.70 price target. To see the full list of analyst forecasts on Cyclopharm Limited stock, see the AU:CYC Stock Forecast page.

Cyclopharm Secures U.S. Patent Extension for Technegas® to 2031
Jun 10, 2025

Cyclopharm Limited has secured a five-year patent extension for its Technegas® Kit in the United States, extending exclusivity until 2031. This extension provides a significant competitive advantage in the U.S. market, allowing Cyclopharm to capitalize on the commercial and clinical potential of Technegas® without the threat of generic competition. The extension underscores the strong clinical profile of Technegas® and supports Cyclopharm’s strategic efforts to expand its market presence and innovation in pulmonary imaging technologies.

The most recent analyst rating on (AU:CYC) stock is a Buy with a A$2.70 price target. To see the full list of analyst forecasts on Cyclopharm Limited stock, see the AU:CYC Stock Forecast page.

Cyclopharm Limited Secures Shareholder Approval for Key Resolutions at AGM
May 30, 2025

Cyclopharm Limited announced that all resolutions proposed at its Annual General Meeting on May 30, 2025, were successfully passed. This includes approvals related to remuneration reports, director re-elections, and performance rights grants, which reflect strong shareholder support and may positively impact the company’s governance and operational strategies.

The most recent analyst rating on (AU:CYC) stock is a Buy with a A$2.70 price target. To see the full list of analyst forecasts on Cyclopharm Limited stock, see the AU:CYC Stock Forecast page.

Cyclopharm Limited Releases Cautious Financial Projections
May 30, 2025

Cyclopharm Limited has released a presentation containing forward-looking statements and projections about its future financial performance and market conditions. The company emphasizes that these projections are based on assumptions and are subject to uncertainties, and it does not guarantee their accuracy. The release highlights the company’s cautious approach to future predictions and its focus on managing stakeholder expectations.

The most recent analyst rating on (AU:CYC) stock is a Buy with a A$2.70 price target. To see the full list of analyst forecasts on Cyclopharm Limited stock, see the AU:CYC Stock Forecast page.

Cyclopharm Achieves Record Sales with US Expansion in 2024
May 30, 2025

Cyclopharm Limited reported a record year in 2024, marked by the commencement of commercial sales in the United States following FDA approval. The company’s revenue reached $27.6 million, with Technegas sales contributing significantly. Despite a loss after tax of $13.2 million, Cyclopharm’s strategic expansion into the US market and its growing third-party distribution business are set to drive future growth. The company’s focus on expanding the use of Technegas for conditions beyond pulmonary embolism, such as COPD and asthma, indicates potential for accessing larger markets and achieving long-term growth.

The most recent analyst rating on (AU:CYC) stock is a Buy with a A$2.70 price target. To see the full list of analyst forecasts on Cyclopharm Limited stock, see the AU:CYC Stock Forecast page.

Cyclopharm Limited Expands US Market Presence with Technegas™
May 30, 2025

Cyclopharm Limited has entered a new growth phase following the USFDA approval of Technegas™ for lung imaging, which has significantly boosted its sales in the United States. The company achieved a 131% increase in US sales in 2024, with continued momentum into 2025, and has secured key agreements with major healthcare providers, enhancing its market reach. The expansion into the US market is expected to accelerate research into new clinical applications, potentially unlocking a global market opportunity estimated at US$900 million. Additionally, Cyclopharm is strengthening its third-party distribution business, contributing to its revenue diversity and margin resilience.

The most recent analyst rating on (AU:CYC) stock is a Buy with a A$2.70 price target. To see the full list of analyst forecasts on Cyclopharm Limited stock, see the AU:CYC Stock Forecast page.

Cyclopharm Limited Announces 2025 Annual General Meeting
Apr 29, 2025

Cyclopharm Limited has announced its Annual General Meeting, scheduled for May 30, 2025, in Kingsgrove, NSW. The meeting will address several key resolutions, including financial statements, director re-election, and approval of performance rights and remuneration. This meeting is crucial for stakeholders as it will determine strategic decisions impacting the company’s governance and financial strategies.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 19, 2025